Nuvectis Pharma, Inc. (NASDAQ:NVCT) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of Nuvectis Pharma, Inc. (NASDAQ:NVCT) have received a consensus rating of “Moderate Buy” from the five analysts that are currently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, three have issued a buy rating and one has issued a strong buy rating on the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $36.25.

Several analysts have recently commented on NVCT shares. UBS Group set a $33.00 price target on shares of Nuvectis Pharma in a research report on Monday, July 6th. HC Wainwright reiterated a “buy” rating and set a $39.00 target price on shares of Nuvectis Pharma in a report on Thursday, September 24th. Roth Capital raised their price target on Nuvectis Pharma from $20.00 to $33.00 and gave the stock a “buy” rating in a research report on Monday, July 6th. Loop Capital set a $40.00 price objective on Nuvectis Pharma in a research report on Tuesday, September 1st. Finally, Lucid Cap Mkts upgraded Nuvectis Pharma to a “strong-buy” rating in a research report on Tuesday, September 1st.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in NVCT. Legal & General Group Plc acquired a new position in shares of Nuvectis Pharma in the second quarter valued at approximately $31,000. Bank of America Corp DE purchased a new stake in Nuvectis Pharma in the 2nd quarter worth approximately $218,000. Avalon Trust Co acquired a new position in Nuvectis Pharma in the 2nd quarter valued at $257,000. Deutsche Bank AG acquired a new position in Nuvectis Pharma in the 2nd quarter valued at $310,000. Finally, Bank of New York Mellon Corp acquired a new position in Nuvectis Pharma in the 2nd quarter valued at $676,000. 96.77% of the stock is currently owned by hedge funds and other institutional investors.

Nuvectis Pharma Stock Performance

Shares of NVCT stock opened at $21.92 on Tuesday. The stock has a market cap of $715.47 million, a PE ratio of -16.73 and a beta of -0.24. Nuvectis Pharma has a 1 year low of $5.55 and a 1 year high of $29.27. The stock has a fifty day moving average price of $21.86 and a 200 day moving average price of $15.68.

Nuvectis Pharma (NASDAQ:NVCT) last issued its quarterly earnings data on Tuesday, August 4th. The company reported ($0.30) EPS for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.04). As a group, equities research analysts predict that Nuvectis Pharma will post -1.01 earnings per share for the current year.

Nuvectis Pharma Company Profile

Nuvectis Pharma, Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients with cancer and other serious unmet medical needs. The company’s research and development programs are centered on novel small-molecule medicines designed to target biological pathways involved in tumor growth and treatment resistance.

Nuvectis’ lead product candidate, NXP800, is an orally administered investigational inhibitor of the heat shock factor 1 pathway. It is being evaluated in clinical studies for advanced solid tumors, including ovarian cancer and other tumor types in which this pathway may play a role.